Eight‐year efficacy and safety of tenofovir alafenamide for treatment of chronic hepatitis B virus infection: Final results from two randomised phase 3 trials
Alimentary Pharmacology & Therapeutics · 2024-12 · 60 (11-12) · 1573-1586
DOI: 10.1111/apt.18278 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Alimentary Pharmacology & Therapeutics, online erschienen am 27.09.2024. Verfasst von Maria Buti und 22 weiteren Autor:innen. Beteiligte Einrichtung: Hospital Universitario Vall d'Hebron, Barcelona, Spain. Hauptthemen laut MEDLINE: Tenofovir, Hepatitis B, Chronic, Alanine, Antiviral Agents. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Gilead Sciences.
Abstract (Originalsprache)
Background
In two phase 3 studies, tenofovir alafenamide (TAF) showed non‐inferior efficacy versus tenofovir disoproxil fumarate (TDF), with more favourable renal and bone safety in patients with chronic hepatitis B (CHB).
Aims
Here, we report the studies' final 8‐year results.
Methods
CHB patients (hepatitis B e antigen [HBeAg]‐negative and HBeAg‐positive) were randomised (2:1) to double‐blind TAF 25 mg/day or TDF 300 mg/day for up to 3 years, followed by open‐label (OL) TAF through year 8. Virological, biochemical, serological and fibrosis responses, and safety, including bone and renal parameters, were evaluated. Resistance to TAF was assessed annually by deep sequencing of polymerase/reverse transcriptase and by phenotyping.
Results
Among 1298 patients randomised to double‐blind TAF ( n = 866) or double‐blind TDF ( n = 432), 775 in the TAF group and 382 in the TDF group received OL TAF, including 180 and 202 who switched from TDF to TAF at year 2 (TDF2y → TAF6y) or year 3 (TDF3y → TAF5y), respectively. At year 8, among patients in the TAF8y, TDF2y → TAF6y and TDF3y → TAF5y groups, 69%, 66% and 73% (missing‐equals‐failure analysis) and 95%, 94% and 97% (missing‐equals‐excluded) of patients, respectively, achieved HBV DNA
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Hospital Universitario Vall d'Hebron, Barcelona, Spain.
- CIBEREHD del Instituto Carlos III, Madrid, Spain.
- Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
- Faculty of Medicine, The Chinese University of Hong Kong, HMA Office, Tai Wai, Shatin, Hong Kong.
- Institute of Liver Studies, King's College Hospital NHS Foundation Trust, London, UK.
- Hepatology Department, Hôpital Beaujon, APHP, INSERM, University of Paris, Clichy, France.
ORCID-Profile: Maria Buti, Young-Suk Lim, Leland J Yee, Wai-Kay Seto
Förderung
- Gilead Sciences
Zitieren
APA
Buti, M., Lim, Y. S., Chan, H. L. Y., Agarwal, K., Marcellin, P., Brunetto, M. R., Chuang, W. L., Janssen, H. L. A., Fung, S. K., Izumi, N., Jablkowski, M. S., Abdurakhmanov, D., Abramov, F., Wang, H., Botros, I., Yee, L. J., Mateo, R., Flaherty, J. F., Osinusi, A., …, & Gane, E. J. (2024). Eight‐year efficacy and safety of tenofovir alafenamide for treatment of chronic hepatitis B virus infection: Final results from two randomised phase 3 trials. Alimentary Pharmacology & Therapeutics, 60(11-12), 1573-1586. https://doi.org/10.1111/apt.18278
Vancouver
Buti M, Lim YS, Chan HLY, Agarwal K, Marcellin P, Brunetto MR, et al. Eight‐year efficacy and safety of tenofovir alafenamide for treatment of chronic hepatitis B virus infection: Final results from two randomised phase 3 trials. Alimentary Pharmacology & Therapeutics. 2024;60(11-12):1573-1586. doi:10.1111/apt.18278
BibTeX
@article{Buti2024,
author = {Buti, Maria and Lim, Young-Suk and Chan, Henry Lik Yuen and Agarwal, Kosh and Marcellin, Patrick and Brunetto, Maurizia R and Chuang, Wan-Long and Janssen, Harry L A and Fung, Scott K and Izumi, Namiki and Jablkowski, Maciej S and Abdurakhmanov, Dzhamal and Abramov, Frida and Wang, Hongyuan and Botros, Irina and Yee, Leland J and Mateo, Roberto and Flaherty, John F and Osinusi, Anu and Pan, Calvin Q and Shalimar, X and Seto, Wai-Kay and Gane, Edward J},
title = {Eight‐year efficacy and safety of tenofovir alafenamide for treatment of chronic hepatitis B virus infection: Final results from two randomised phase 3 trials},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2024},
volume = {60},
number = {11-12},
pages = {1573--1586},
doi = {10.1111/apt.18278}
}
EUVIMED